Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience

被引：0

作者：

Nesr, George ^{[1
]}

Shah, Raakhee ^{[1
]}

Kyriakou, Charalampia ^{[1
]}

Sive, Jonathan ^{[1
]}

Popat, Rakesh ^{[1
]}

Yong, Kwee ^{[1
]}

Wisniowski, Brendan ^{[1
]}

Xu, Ke ^{[1
]}

Wechalekar, Ashu ^{[1
]}

Lee, Lydia ^{[1
]}

Ings, Stuart ^{[1
]}

Papanikolaou, Xenofon ^{[1
]}

Mahmood, Shameem ^{[1
]}

Mcmillan, Annabel ^{[1
]}

Horder, Jackie ^{[1
]}

Newrick, Fiona ^{[1
]}

Marfil, Jotham ^{[1
]}

Ainley, Louise ^{[1
]}

Asher, Samir ^{[1
]}

Cheesman, Simon ^{[1
]}

Rabin, Neil ^{[1
]}

机构：

[1] Univ Coll London Hosp NHS Fdn Trust, Haematol Dept, London, England

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 08期

关键词：

Multiple myeloma; renal impairment; autologous stem cell transplantation; 200 MG/M(2); INTRAVENOUS MELPHALAN; PHASE-II; TRANSPLANTATION; PHARMACOKINETICS; TOXICITY; FAILURE; TRIAL;

D O I：

10.1080/10428194.2023.2216817

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High dose melphalan (HDM) followed by autologous stem cell transplantation (ASCT) remains the standard consolidation in transplant eligible multiple myeloma (MM) patients. The timing between HDM administration and hematopoietic stem cell return (HSCR) varies among institutions, with a 'rest period' of 48 hours (h) employed by some for patients with renal impairment (RI). We investigated the differences in hematopoietic recovery and HDM toxicity between MM patients with RI who had HSCR after 24 vs 48 h from HDM. Fifty MM patients with RI (48 h group; n = 31 and 24 h group; n = 19) were included. No statistically significant differences were noted in surrogates for hematopoietic recovery and HDM toxicity between both groups. Only one death occurred in the 24 h group. No patients required renal replacement therapy. Therefore, a 24 h period between HDM and AHSC infusion appears safe for MM patients with RI.

引用

页码：1465 / 1471

页数：7

共 32 条

[1] Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma [J].

Abudayyeh, Ala ;

Lin, Heather ;

Mamlouk, Omar ;

Abdelrahim, Maen ;

Saliba, Rima ;

Rondon, Gabriela ;

Martinez, Charles S. ;

Delgado, Ruby ;

Page, Valda ;

Rajasekaran, Arun ;

Sanders, Paul W. ;

Qazilbash, Muzaffar .

LEUKEMIA & LYMPHOMA, 2020, 61 (13) :3101-3111

[2] Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant [J].

Al Saleh, Abdullah S. ;

Sidiqi, M. Hasib ;

Lee, JaeWon ;

Dispenzieri, Angela ;

Muchtar, Eli ;

Buadi, Francis K. ;

Warsame, Rahma ;

Lacy, Martha Q. ;

Dingli, David ;

Leung, Nelson ;

Gonsalves, Wilson I. ;

Kapoor, Prashant ;

Kourelis, Taxiarchis V. ;

Skaer, Christel A. ;

Wittwer, Sarah K. ;

Wolf, Robert C. ;

Hogan, William J. ;

Kumar, Shaji K. ;

Jacob, Eapen ;

Gertz, Morie A. .

BONE MARROW TRANSPLANTATION, 2020, 55 (11) :2132-2137

[3]

ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P73

[4] Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma [J].

Andronesi, Andreea G. ;

Tanase, Alina D. ;

Sorohan, Bogdan M. ;

Craciun, Oana G. ;

Stefan, Laura ;

Varady, Zsofia ;

Lipan, Lavinia ;

Obrisca, Bogdan ;

Truica, Alexandra ;

Ismail, Gener .

CANCER MEDICINE, 2019, 8 (06) :3278-3285

[5] Results of autologous stem cell transplant in multiple myeloma patients with renal failure [J].

Badros, A ;

Barlogie, B ;

Siegel, E ;

Roberts, J ;

Langmaid, C ;

Zangari, M ;

Desikan, R ;

Shaver, MJ ;

Fassas, A ;

McConnell, S ;

Muwalla, F ;

Barri, Y ;

Anaissie, E ;

Munshi, N ;

Tricot, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (04) :822-829

[6]

Bergel F., 1953, Br Emp. Cancer Comp. Annu., V31, P6

[7]

Cancer Research UK, 2021, MYEL INC STAT

[8] Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy:: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival [J].

Carlson, K .

BONE MARROW TRANSPLANTATION, 2005, 35 (10) :985-990

[9] Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma [J].

Clark, AD ;

Shetty, A ;

Soutar, R .

BLOOD REVIEWS, 1999, 13 (02) :79-90

[10] Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group [J].

Dimopoulos, Meletios A. ;

Terpos, Evangelos ;

Chanan-Khan, Asher ;

Leung, Nelson ;

Ludwig, Heinz ;

Jagannath, Sundar ;

Niesvizky, Ruben ;

Giralt, Sergio ;

Fermand, Jean-Paul ;

Blade, Joan ;

Comenzo, Raymond L. ;

Sezer, Orhan ;

Palumbo, Antonio ;

Harousseau, Jean-Luc ;

Richardson, Paul G. ;

Barlogie, Bart ;

Anderson, Kenneth C. ;

Sonneveld, Pieter ;

Tosi, Patrizia ;

Cavo, Michele ;

Rajkumar, S. Vincent ;

Durie, Brian G. M. ;

San Miguel, Jesus .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) :4976-4984

← 1 2 3 4 →